By Integrated Diabetes Services
A new ultra-rapid insulin is showing encouraging results for adults with type 1 diabetes.
This ultra-rapid insulin offers faster post-meal blood sugar control without compromising overall glucose management.
- Drug: BioChaperone Lispro (THDB0206), an ultra-rapid insulin.
- Trial: Phase 3 in 550 adults; compared to standard insulin Humalog.
- Results: Controlled HbA1c as well as Humalog and reduced post-meal blood sugar spikes.
- Safety: Mostly mild or moderate side effects, similar to standard insulin.
Why This Matters for Type 1 Diabetes Management
Managing type 1 diabetes can be challenging, especially around meals. Blood sugar can spike quickly after eating, and standard insulins don’t always act fast enough to prevent these post-meal highs.
Ultra-rapid insulin like THDB0206 works faster than standard insulin, helping to:
- Reduce post-meal blood sugar spikes for more stable glucose levels.
- Improve overall blood sugar control without increasing the risk of low blood sugar.
- Give patients more flexibility with meal timing and lifestyle, since the insulin acts quickly.
By smoothing out blood sugar fluctuations, ultra-rapid insulin may help people with type 1 diabetes better manage daily highs and lows, potentially reducing long-term complications and making day-to-day diabetes management easier and more predictable.
